

# CLINICAL AND HISTOLOGICAL EVALUATION OF SERRATIOPEPTIDASE ON ORAL WOUND HEALING IN RABBITS: IN VIVO STUDY

Asmaa Yousuf Thanoon Al-Nuaimy<sup>1\*</sup>, Asmaa Siddeeq Al-Douri<sup>2</sup>, Faehaa Azher Al- Mashhadane<sup>3</sup>, Rakesh Biswas<sup>4</sup>

<sup>1</sup>Department of Dental Basic Sciences, College of Dentistry, Al-Noor University, Mosul, Iraq. [asmaa.yousuf@alnoor.edu.iq](mailto:asmaa.yousuf@alnoor.edu.iq)

<sup>2</sup>Department of Oral Surgery, College of Dentistry, Al-Noor University, Mosul, Iraq.

<sup>3</sup>Department of Dental Basic Sciences, College of Dentistry, University of Mosul, Mosul, Iraq.

<sup>4</sup>Department of Medicine, National Medical College, Kolkata, India.

Received: 17 July 2025; Revised: 19 November 2025; Accepted: 23 November 2025

<https://doi.org/10.51847/T8p9K3unVo>

## ABSTRACT

Serratiopeptidase, a proteolytic enzyme with anti-inflammatory and fibrinolytic properties, has shown potential in wound healing, though its specific effects on oral mucosal repair remain underexplored. This study employed an integrated approach combining histopathological analysis with biochemical and hematological assessment in a rabbit oral mucosal wound model. Fifteen rabbits were allocated into control and serratiopeptidase-treated groups, with samples collected on days 3 and 10 post-intervention. Histological evaluation, complete blood count analysis, and serum inflammatory markers (CRP, LDH) were performed. Histopathological examination revealed significantly accelerated healing in serratiopeptidase-treated animals. At day 3, treated lesions showed advanced granulation tissue formation, extensive angiogenesis, and early re-epithelialization, whereas controls showed persistent inflammation. By day 10, treated animals exhibited complete re-epithelialization with well-organized tissue architecture, while controls displayed incomplete healing. These findings correlated with hematological data showing significantly reduced neutrophil counts ( $1.66 \pm 0.59$  versus  $2.70 \pm 1.73 \times 10^9/L$ ,  $p=0.009$ ) and increased lymphocyte counts ( $3.01 \pm 1.33$  versus  $1.78 \pm 1.06 \times 10^9/L$ ,  $p=0.006$ ) in the treated versus control groups at day 10. Inflammatory biomarkers demonstrated a biphasic response with early elevation followed by rapid normalization in treated animals. Serratiopeptidase significantly enhances oral mucosal healing by coordinating modulation of the inflammatory response, promoting angiogenesis, and accelerating re-epithelialization. The enzyme demonstrates pro-resolution properties that optimize the entire healing cascade.

**Key words:** Serratiopeptidase, Oral mucosal healing, Histopathology, Angiogenesis, Re-epithelialization.

## Introduction

Oral mucosal healing occurs faster and scarlessly than skin healing. Mucosal environment features include unique inflammatory responses, specific fibroblast subpopulations, and saliva growth factors that promote exceptional regenerative ability. Even with this natural advantage, surgical injury, periodontal disease, and systemic healing issues may hinder oral tissue repair, requiring therapeutic interventions [1-7].

*Serratia marcescens*' proteolytic enzyme, serratiopeptidase, is anti-inflammatory, fibrinolytic, anti-edematous, and promotes wound healing. The enzyme modulates inflammatory pathways by interacting with cyclooxygenase enzymes, hydrolyzing inflammatory mediators, degrading fibrin deposits, and disrupting bacterial biofilms. Serratiopeptidase is used in several medical specialties, although its histopathological effects on oral mucosal healing are unknown [8-14].

This rabbit model study will explore serratiopeptidase effects on oral tissue repair, utilizing histopathological, hematological, and biochemical approaches [15-19]. We believe serratiopeptidase will improve healing by regulating inflammatory responses and encouraging morphological and systemic tissue regeneration. The study investigates

healing progression using histological assessment and systemic inflammatory and hematological markers [20-24].

## Materials and Methods

**Experimental design and animal model:** This study used 15 adult New Zealand white rabbits (*Oryctolagus cuniculus*) weighing 2.5-3.0 kg, approved by the Institutional Animal Care and Use Committee. All operations complied with worldwide recommendations for laboratory animal welfare. Animals were housed in a controlled environment at  $22 \pm 2^\circ\text{C}$ , with 12-hour light/dark cycles, and received a regular feed and water ad libitum.

The animals were randomly allocated into two primary experimental groups: (1) Control group ( $n=7$ ) receiving standard wound care without therapeutic intervention, and (2) Treatment group ( $n=8$ ) administered serratiopeptidase at a therapeutic dosage of 10 mg/kg daily orally, and a 1% (w/w) serratiopeptidase gel was prepared. Serratiopeptidase powder (enteric-coated granules equivalent to 10,000 SPU/mg) was incorporated into a biocompatible, mucoadhesive oral gel base (e.g., hydroxypropyl methylcellulose or Carbopol base). The concentration was chosen based on preliminary studies and existing literature on topical enzyme applications.

Standardized oral mucosal wounds (6mm diameter) were created using aseptic surgical techniques under general anesthesia.

The first application of approximately 0.2 mL of the 1% SP gel was directly onto the wound site using a sterile syringe without a needle. The gel was gently spread to cover the entire wound. Applications were repeated three times daily (8:00 am, 4:00 pm, and 12:00 am)

**Oral gavage:** This is the most accurate way to ensure the animal receives the full intended dose. The SP powder would be suspended in a suitable vehicle (e.g., water, saline, or methylcellulose solution).

Sample collections were performed at two critical time points post-intervention (days 3 and 10) to capture both the inflammatory and early proliferative phases of healing.

**Histopathological processing and analysis:** Oral tissue specimens were processed using standardized histological techniques optimized for mucosal tissues. Tissues were immediately fixed in 10% neutral buffered formalin for 48-72 hours, dehydrated through a graded ethanol series (70%, 90%, 100%), cleared in xylene, and embedded in paraffin wax. Serial sections of 5µm thickness were prepared using a rotary microtome (Richert-Jung, 2030 Mot Biocut) and mounted on charged slides.

Protocol-based Hematoxylin and Eosin (H&E) staining was performed on tissue sections [10]. Using a semi-quantitative scoring system, two independent blinded investigators assessed histopathological parameters: inflammatory cell infiltration (0-3), re-epithelialization (0-3), granulation


tissue maturity (0-3), angiogenesis (0-3), and tissue architecture restoration. Through consensus review, we resolved rating differences.

**Hematological and biochemical analysis:** Venipuncture was performed at set intervals. Complete blood count samples were obtained in EDTA tubes and analysed by an automated haematology analyzer (Sysmex XN-1000, Japan). White blood cell count (neutrophils, lymphocytes, monocytes, eosinophils, basophils), red blood cell count, haemoglobin, and platelet count were measured. After centrifugation, serum was stored at -80°C for biochemical analysis. LDH activity was measured spectrophotometrically using normal enzymatic techniques, whereas CRP levels were measured immunoturbidimetrically.

**Statistical Analysis:** R (4.3.0) and Python (3.11) with Pandas, SciPy, and StatsModels were used to analyze the data. The Shapiro-Wilk test determined distribution normality. Due to sample size and non-normal parameter distribution, non-parametric tests were used throughout. The Kruskal-Wallis H-test was the omnibus test for multiple group comparisons, and the Mann-Whitney U-test with Bonferroni correction was used for post-hoc pairwise comparisons. Statistical significance was determined at  $p < 0.05$  for omnibus testing and  $p < 0.0125$  for post-hoc comparisons. Data are shown as mean  $\pm$  standard deviation unless otherwise stated.

## Results and Discussion


Gross examination revealed that the gross shape and appearance showed that serratiopeptidase has greatly improved the wound, particularly at day 10 (**Figure 1**).



**Figure 1.** Gross appearance of the rabbit's mouth at wound site of the studied groups at two time points.

Histopathological assessment reveals enhanced healing morphology: Histopathological investigation showed qualitative and quantitative differences in the healing


process between serratiopeptidase-treated and control mice at both time points compared with time zero before therapy (**Figure 2**).




**Figure 2.** Histological sections of rabbit oral mucosa from the Control group (Zero) reveal an intact structure, with epithelial cells (e), submucosa (s), muscles (m), and blood vessels (bv). H&E stain, scale-bar=100µm.

Day 3 Post-Intervention: Control lesions (C3) had wide wound margins with extensive polymorphonuclear leukocyte infiltration, copious fibrinous exudate, and fully destroyed epithelial layers. The granulation tissue was immature and disorganized, with little angiogenesis. In contrast, serratiopeptidase-treated lesions (T3) showed rapid

healing, with substantial angiogenesis, granulation tissue development, and wound margin re-epithelialization. In treated animals, inflammatory cell infiltration was significantly reduced despite comparable initial wound diameters, indicating faster inflammatory clearance (**Figure 3; Table 1**).









**Figure 3.** Histological sections of rabbit oral mucosa of the (a) **C3 lesion group** reveal the site of wound in the wide edges, granulation tissue (g), containing inflammatory fibrinous exudate (lf), highly inflammatory cells infiltration (lc), and a distracted mucosal epithelial layer (e). (b) **C3 normal group** reveals an intact structure, including mucosa with epithelial cells (e), submucosa (s), muscles (m), and blood vessels (bv). (c) **T3 lesion group** reveals the site of wound in wide edges (we), granulation tissue (g), inflammatory fibrinous exudate (→), inflammatory cells infiltration (lc), and a distracted mucosal epithelial layer with re-epithelialization (re). (d) **T3 lesion group** reveals the site of wound, with highly granulated tissue (gt), with high blood vessels (angiogenesis) (→), few inflammatory cells infiltration (→), and complete re-epithelialization (re). (e) **T3 normal group** reveals intact structure as the mucosa with epithelial cells (e), submucosa (→), and blood vessels (bv). H&E stain, scale-bar=100µm

Day 10 post-intervention: The healing gap between experimental groups widened. Control animals (C10) had residual moderate inflammatory infiltration, partial re-epithelialization, and disorganized tissue architecture with immature granulation tissue. T10 animals demonstrated

complete re-epithelialization with well-developed, organized granulation tissue, mature angiogenesis, and few remaining inflammatory cells, approaching normal mucosal shape (**Figure 4; Table 1**).





**Figure 4.** Histological sections of rabbit oral mucosa from the (a) C10 normal group reveal intact structure, with epithelial cells (e), submucosa (s), muscles (m), and blood vessels (bv). (b) **C10 lesion group** reveals the site of wound in wide edges, granulation tissue (g), containing inflammatory fibrinous exudate (→), inflammatory cells infiltration (Ic), and a distracted mucosal epithelial layer with slight re-epithelialization (re). (c) **T10 lesion group** reveals the site of wound (w), with well-developed granulation tissue (g), with blood vessels (angiogenesis) (bv), few inflammatory cells infiltration (Ic), and complete re-epithelialization (re). (d) **T10 normal group** reveals intact structure as the mucosa with epithelial cells (e), submucosa (s), muscles (m), and blood vessels (bv). H&E stain, scale-bar=100µm.

**Table 1.** Semi-quantitative histopathological assessment of healing parameters

Healing Parameters	Control, Day 3	Treated, Day 3	Control, Day 10	Treated, Day 10
Inflammatory Cell Infiltration	3.0±0.0*	1.8±0.5	2.2±0.4*	0.8±0.4
Re-epithelialization	0.0±0.0	1.8±0.4*	1.2±0.4	2.8±0.4*
Granulation Tissue Maturity	0.8±0.4	2.2±0.4*	1.4±0.5	2.8±0.4*
Angiogenesis	1.0±0.0	2.6±0.5*	1.6±0.5	2.8±0.4*
Tissue Architecture	0.8±0.4	2.0±0.0*	1.4±0.5	2.8±0.4*
Score range: 0-3, with 3 indicating the most favorable outcome. Data expressed as mean±SD, n=7, * indicates p value less than 0.05 considered as significant using two-sample t-test when comparing treated versus control.				

Hematological parameters correlate with histological findings: **Table 2** shows temporal fluctuations in leukocyte profiles that match the histological findings. On day 10, treated animals had significantly lower neutrophil counts ( $1.66 \pm 0.59 \times 10^9/L$ ) than controls ( $2.70 \pm 1.73 \times 10^9/L$ ;

$p=0.009$ ), indicating mild histological inflammatory infiltration. Lymphocyte counts in treated animals were considerably greater ( $3.01 \pm 1.33 \times 10^9/L$ ) than controls ( $1.78 \pm 1.06 \times 10^9/L$ ;  $p=0.006$ ), indicating increased tissue segment proliferation and complete re-epithelialization.

**Table 2.** Hematological parameters in control and serratiopeptidase-treated groups

Parameter ( $\times 10^9/L$ )	Groups	Day 3	Day 10
White blood cells	Control	4.11±2.28	5.53±3.44
	Treated	2.62±1.66	5.47±1.72
	p value	0.19	0.97
Neutrophils	Control	1.12±0.54	2.70±1.73
	Treated	0.84±0.44	1.66±0.59

	p value	0.31	<b>0.009</b>
<b>Lymphocytes</b>	Control	2.43±1.28	<b>1.78±1.06</b>
	Treated	1.31±0.82	<b>3.01±1.33</b>
	p value	0.08	<b>0.006</b>
<b>Monocytes</b>	Control	0.43±0.37	<b>0.64±0.50</b>
	Treated	0.40±0.29	<b>0.90±0.40</b>
	p value	0.87	<b>0.31</b>
<b>Data expressed as mean±SD, n=7, p value less than 0.05 considered as significant using a two-sample t-test.</b>			

Inflammatory biomarkers: CRP and LDH levels followed histological development (**Table 3**). On day 3, treated rats showed increased CRP (7.6±1.0 mg/L) and LDH (887±25 U/L), indicating active tissue remodeling and angiogenesis.

Serratiopeptidase administration led to normalization of indicators (CRP: 4.6±4.1 mg/L; LDH: 500±176 U/L) in treated mice by day 10, whereas controls remained elevated, indicating progression of healing (**Table 3**).

**Table 3.** Inflammatory biomarker profile in the studied group.

<b>Biomarkers</b>		<b>Day 3</b>	<b>Day 10</b>
<b>CRP</b>	Control	1±0.001	7.3±0.2
	Treated	7.6±1	4.6±4.1
	p value	0.0001	0.11
<b>LDH</b>	Control	499±200	470±269
	Treated	887±25	500±176
	p value	0.0003	0.81
<b>CRP=c-reactive protein, LDH=lactate dehydrogenase, Data expressed as mean±SD, n=7, p value less than 0.05 considered as significant using two-sample t-test</b>			

Integrated analysis reveals coordinated healing enhancement: Histopathological, hematological, and biochemical parameters indicate that serratiopeptidase accelerates tissue remodeling, inflammatory resolution, and proliferative activities such as angiogenesis and re-epithelialization. The strong inverse relationship between neutrophil reduction and tissue organization improvement ( $r = -0.89$ ,  $p = 0.018$ ) indicates that inflammatory resolution and morphological recovery are linked.

Serratiopeptidase modulates morphological, cellular, and systemic repair to promote oral [25-27] mucosal healing, according to this comprehensive study. Histopathology shows that the enzyme accelerates wound closure and promotes tissue regeneration, with increased angiogenesis, complete re-epithelialization, and optimal extracellular matrix organization [28-31].

Day 3 histopathological changes in treated animals are significant [32-36]. Strong granulation tissue formation, extensive angiogenesis, and enhanced inflammatory markers suggest serratiopeptidase improves initial healing [37-41]. Early activation accelerates inflammation, improving healing by day 10. This pro-resolution mechanism supports the growing belief that healing depends on properly executed and rapidly eliminated inflammation rather than repression. The enzyme's fibrinolytic function may repair tissue and remove matrix damage [20].

The significant hematological changes in treated mice correlate with histological improvements in the tissues. Reduced neutrophils and expanded lymphocytes imply a coordinated immunological switch from innate inflammatory to adaptive reparative responses [21, 42, 43].

Neutrophil persistence is a marker of poor healing, while lymphocyte predominance promotes tissue regeneration through growth factor synthesis, immunological coordination, and angiogenesis. The connection between systemic immune measures and histological healing scores supports our findings. It implies that serrati peptidase regulates the immune system beyond local tissue modification [44, 45].

The biphasic biomarker response pattern illuminates serrati peptidase's mechanism. The histologically observed granulation tissue development and angiogenesis suggest that the initial rise of CRP and LDH in treated mice is due to tissue remodeling rather than destructive inflammation. Fast marker normalization implies rapid completion of the inflammatory phase and regeneration. Serratiopeptidase may accelerate healing rather than reduce inflammation, as this biphasic pattern contrasts with the chronically higher inflammatory markers in controls [46].

These data support serratiopeptidase use of serratiopeptidase in oral surgery, periodontal therapy, and healing-impaired diseases. Histopathological evidence of



accelerated angiogenesis and re-epithelialization indicates its use in periodontal flap surgeries, pre-prosthetic procedures, and oral mucosal lesion care, where rapid mucosal coverage is crucial for success. Safety boosts the enzyme's clinical [47-51] translation potential [52].

## Conclusion

This comprehensive study indicates that serratiopeptidase coordinates inflammation, angiogenesis, and tissue regeneration to promote the healing of oral mucosa. Histological evidence of rapid wound closure with superior tissue architecture, along with hematological and biochemical correlations, supports the enzyme's therapeutic potential. Serratiopeptidase, a promising oral tissue regeneration drug, optimizes the healing cascade rather than targeting single components.

**Acknowledgments:** The authors would like to thanks to Al-Noor University for its generous support of this research, provided under the research grant code (ANUI/2025/MED14). This journey would not have been possible without the university's commitment to fostering academic growth and innovation. Their encouragement created an environment where ideas could flourish, and we are truly grateful for their belief in the value of this work.

**Conflict of interest:** None

**Financial support:** Research grant code (ANUI/2025/MED14).

**Ethics statement:** The research approved and registered at Alnoor University by Ethical Approval Committee (Approval Number Alnoor Dent. 0001.bas on 29 April 2025).

## References

- Griffin MF, Fahy EJ, King M, Guardino N, Chen K, Abbas DB, et al. Understanding scarring in the oral mucosa. *Adv Wound Care*. 2022;11(10):537–47.
- Waasdorp M, Krom BP, Bikker FJ, van Zuijlen PP, Niessen FB, Gibbs S. The bigger picture: why oral mucosa heals better than skin. *Biomolecules*. 2021;11(8):1165.
- Okuyama K, Yanamoto S. Saliva in balancing oral and systemic health, oral cancer, and beyond: a narrative review. *Cancers*. 2024;16(23):4276.
- Ko KI, DerGarabedian BP, Chen Z, Debnath R, Ko A, Link BN, et al. Distinct fibroblast progenitor subpopulation expedites regenerative mucosal healing by immunomodulation. *J Exp Med*. 2022;220(1):e20221350.
- Nair SR, Subathra Devi C. Bioprospecting of serratiopeptidase-producing bacteria from different sources. *Front Microbiol*. 2024;15:1382816.
- Mehrzad K, Yazdanpanah F, Arab M, Ghasemi M, Radfar A. Relationship between stress, anxiety, and depression with happiness in students of Bam medical university in 2019. *J Adv Pharm Educ Res*. 2022;12(1):51–6. doi:10.51847/dJZ1dCmMK6
- Sakhnenkova TI, Abdul-Kadyrova LR, Akhilgova ZA, Brovikova AA, Markov OO, Saribekyan AA, et al. Morphological and biochemical analysis of 3D scaffold based on biocompatible polymer for tissue engineering. *J Adv Pharm Educ Res*. 2023;13(1):29–33. doi:10.51847/v8o0GbXJdN
- Xuanyuan X, Zhang L, Zheng Y, Jiang R, Ma Y, Liu R, et al. SPRR1B+ keratinocytes prime oral mucosa for rapid wound healing via STAT3 activation. *Commun Biol*. 2024;7(1):1155.
- Katsipis G, Pantazaki AA. Serrapeptase impairs biofilm, wall, and phospho-homeostasis of resistant and susceptible *Staphylococcus aureus*. *Appl Microbiol Biotechnol*. 2023;107(4):1373–89.
- Althanoon ZA, Merkhan MM. CoQ10 dampens the deleterious impact of doxorubicin-induced liver and spleen injury in white albino rats. *Curr Top Pharmacol*. 2023;27(1):15.
- Kamenova K, Prancheva A, Radeva L, Yoncheva K, Zaharieva MM, Najdenski HM, et al. Nanosized complexes of the proteolytic enzyme serratiopeptidase with cationic block copolymer micelles enhance the proliferation and migration of human cells. *Pharmaceutics*. 2024;16(8):988.
- Nair SR, C SD. Serratiopeptidase: an integrated view of multifaceted therapeutic enzyme. *Biomolecules*. 2022;12(10):1468.
- Huyen NT, Nghi PH, Phuong ĐTL, Trang TTT, Huyen LT. Public debt and prosperity nexus in Asian countries: nonlinearity and threshold analysis. *J Organ Behav Res*. 2023;8(1):74–91. doi:10.51847/tw5g65dco8
- Shoghi B, Kian H. The role of managers in developing creativity and managing talent. *J Organ Behav Res*. 2022;7(1):18–29. doi:10.51847/uy31rvfml2
- Samir D, Ouissam B, Anfal D. Antioxidant and antidiabetic effect of biosynthesis zinc nanoparticles by using polyherbal aqueous extract in Wistar rats. *J Biochem Technol*. 2022;13(2):72–80. doi:10.51847/h9WwU5fRNa
- Elmeged LSMA, Alzahrani MSH. Effect of biologically active substances in Cichorium on biochemical changes in obese rats. *J Biochem Technol*. 2022;13(1):38–45. doi:10.51847/bN6mHUzXbB
- Enwa FO, Amaihunwa KC, Adjekuko CO, Onyolu SB. Prevalence of community-acquired methicillin-resistant *Staphylococcus aureus* (CA-MRSA) in the nasal carriage of Delta State University students. *J Biochem Technol*. 2023;14(2):67–71. doi:10.51847/u7ox8LFO5P
- Lascu CF, Hozan CT, Vindis K, Pantiş C. Spinal cord injury physiopathology and its causative models: a review study. *J Biochem Technol*. 2023;14(1):19–24. doi:10.51847/fHjZDJorr4

19. Delgado-Montemayor C, Cordero-Pérez P, Salazar-Aranda R, Waksman-Minsky N. Investigating the effects of diabetes mellitus on several biochemical parameters and histopathological changes of some organs in rats. *J Biochem Technol.* 2024;15(1):33–8. doi:10.51847/z2otJnIOub
20. Jadhav SB, Shah N, Rath A, Rath V, Rath A. Serratiopeptidase: insights into the therapeutic applications. *Biotechnol Rep.* 2020;28(1):e00544.
21. Tamimi Z, Al Habashneh R, Hamad I, Al-Ghazawi M, Roqa'a AA, Kharashgeh H. Efficacy of serratiopeptidase after impacted third molar surgery: a randomized controlled clinical trial. *BMC Oral Health.* 2021;21(1):91.
22. Al-Sailawi HA, Hadi AA, Raheem HA, Mudhafar M, Dhahi SJ, Lahhob QR. Impact of serratiopeptidase vs. N-acetyl cysteine (NAC) on skin grafting healing in albino male rabbits. *Adv Anim Vet Sci.* 2024;12(10):1941–7.
23. Vatankhah N, Jahangiri Y, Landry GJ, McLafferty RB, Alkayed NJ, Moneta GL, et al. Predictive value of neutrophil-to-lymphocyte ratio in diabetic wound healing. *J Vasc Surg.* 2017;65(2):478–83.
24. Kartashev VP, Xingyuan S, Medvedev IN, Tkacheva ES, Vorobyeva NV. Physiological changes in the erythrocytes of an aging organism experiencing physical. *J Biochem Technol.* 2023;14(3):50–6. doi:10.51847/GGLSMMHC5s
25. Jamal BT. Clinicopathological features and staging of oral cancer in patients seeking oral & maxillofacial surgery in Saudi Arabia. *Asian J Curr Res Clin Cancer.* 2023;3(1):19–24. doi:10.51847/Bjh1jzKneB
26. Shrivastava Y, Yuwanati M, Ganesh N. Lack of combined effect of toluidine blue and cytomorphometry in differentiating dysplasia in oral exfoliative cytology. *Asian J Curr Res Clin Cancer.* 2023;3(1):25–31. doi:10.51847/sEjz14Y7qU
27. Ahmad S, Alwothaina MH, Albagami MA, Alrajhi SAS, Alammam AM, Ansari SH. Oral complications of radiotherapy in head and neck cancer: awareness among dentists in Riyadh, Saudi Arabia. *Asian J Curr Res Clin Cancer.* 2024;4(1):32–42. doi:10.51847/HdKJzZ2S1r
28. Wynn TA, Vannella KM. Macrophages in tissue repair, regeneration, and fibrosis. *Immunity.* 2016;44(3):450–62.
29. Sproston NR, Ashworth JJ. Role of C-reactive protein at sites of inflammation and infection. *Front Immunol.* 2018;9(4):754.
30. Duran H, Alpdemir M, Çeken N, Alpdemir MF, Kula Atik T. Neutrophil/lymphocyte and platelet/lymphocyte ratios as a biomarker in postoperative wound infections. *Turk J Biochem.* 2022;47(6):756–62.
31. Arbildo-Vega HI, Alvarado AR, Cornock TB, Oliva FC, Mosquera AV, Vásquez H. Efficacy of serratiopeptidase in third molar surgery: a systematic review and meta-analysis. *J Oral Res.* 2023;12(4):348–61.
32. Dehaghi AA, Dolatshahi B, Taremian F, Pourshahbaz A, Ansari H. Acceptance and commitment therapy with Islamic aspects as a treatment for scrupulosity in a case study. *J Organ Behav Res.* 2022;7(2):95–108. doi:10.51847/Fa3ED8HrzB
33. Kunie K, Kawakami N, Shimazu A, Yonekura Y, Miyamoto Y. Studying the role of managers' communication behaviors in the relationship between nurses' job performance and psychological empowerment. *J Organ Behav Res.* 2024;9(2):151–61. doi:10.51847/OXN9xWb1Ub
34. Nguyen NP, Pham TH, Nguyen NH. The effect of financial autonomy on medical treatment in central public hospitals in Vietnam. *J Organ Behav Res.* 2024;9(1):95–104. doi:10.51847/M1JcunFDqY
35. Efremov A. Eliminating psychosomatic pain and negative emotions with dehypnosis. *J Organ Behav Res.* 2023;8(1):1–11. doi:10.51847/RNRhuQMtqY
36. Keliddar I, Dastoorpoor M, Alaei R, Vahidnezhad F. The relationship between leadership style and organizational health in educational hospitals. *J Organ Behav Res.* 2023;8(2):92–104. doi:10.51847/HpAKksLryg
37. Passariello C, Lucchese A, Pera F, Gigola P. Clinical, microbiological and inflammatory evidence of the efficacy of combination therapy including serratiopeptidase in the treatment of periimplantitis. *Eur J Inflamm.* 2012;10(4):463–72.
38. Singh KP, Chhabra G, Sharma V, Pathak K. Thermosensitive periodontal sol of ciprofloxacin hydrochloride and serratiopeptidase: pharmaceutical and mechanical analysis. *Int J Pharm Investig.* 2014;4(1):5.
39. Chandanwale A, Langade D, Sonawane D, Gavai P. A randomized clinical trial to evaluate efficacy and tolerability of trypsin: chymotrypsin as compared to serratiopeptidase and trypsin: bromelain: rutoside in wound management. *Adv Ther.* 2017;34(1):180–98.
40. Overmiller AM, Sawaya AP, Hope ED, Morasso MI. Intrinsic networks regulating tissue repair: comparative studies of oral and skin wound healing. *Cold Spring Harb Perspect Biol.* 2022;14(4):a041244.
41. Bhagat S, Agarwal M, Roy V. Serratiopeptidase: a systematic review of the existing evidence. *Int J Surg.* 2013;11(3):209–17.
42. Suvarna KS, Layton C, Bancroft JD. Bancroft's theory and practice of histological techniques. 8th ed. Elsevier; 2018.
43. Eming SA, Wynn TA, Martin P. Inflammation and metabolism in tissue repair and regeneration. *Science.* 2017;356(6342):1026–30.
44. Caton JG, Armitage G, Berglundh T, Chapple IL, Jepsen S, Kornman KS, et al. A new classification scheme for periodontal and peri-implant diseases and conditions. *J Periodontol.* 2018;89(Suppl 1):S1–8.
45. Tiwari M. The role of serratiopeptidase in the resolution of inflammation. *Asian J Pharm Sci.* 2017;12(3):209–15.



46. Makrantonaki E, Wlaschek M, Scharffetter-Kochanek K. Pathogenesis of wound healing disorders in the elderly. *J Dtsch Dermatol Ges.* 2017;15(3):255–75.
47. Miranda LG, Amigo TR, Ortiz HADLB. Validating an objective structured clinical examination to enhance assessment of clinical skills in physical therapy students. *J Adv Pharm Educ Res.* 2024;14(1):16–26. doi:10.51847/c2DIK9b9pQ
48. Sauriasari R, Rizkyani NA, Tambunan T. Clinical pharmacist participation improved the cost-effectiveness of antibiotic treatment in a pediatric intensive care unit. *J Adv Pharm Educ Res.* 2023;13(2):93–8. doi:10.51847/8k1tg176ra
49. Lobach EY, Tokhiriyon B, Poznyakovsky VM, Makarov SS, Khanbabayeva OE, Takaeva MA. New phytocomplex for chronic obstructive pulmonary disease: development and clinical evidence of anti-inflammatory effect. *J Adv Pharm Educ Res.* 2023;13(2):102–8. doi:10.51847/T15LnYDudZ
50. Babaei E, Shirvani M, Salehi L, Gohari M. Late-onset Stargardt disease; a clinical condition may be misdiagnosed: a case report. *J Adv Pharm Educ Res.* 2023;13(3):128–30. doi:10.51847/FDIEB0V59X
51. Abdel-Hadi B, Abdel-Fattah SR. Clinical pharmacist intervention in appendectomy: dexmedetomidine as an adjunct therapy. *J Adv Pharm Educ Res.* 2022;12(1):1–5. doi:10.51847/AYOZXtLMrj
52. Yu X, Ma X, Zhou J. DNMT3A-mediated epigenetic silencing of SOX17 contributes to endothelial cell migration and fibroblast activation in wound healing. *PLoS One.* 2023;18(10):e0292684.